Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Carcinoma, Neuroendocrine 1

Interventions

Gemcitabine 58130-nm albumin-bound paclitaxel 35Specimen Handling 26Fluorouracil 22Albumin-Bound Paclitaxel 22Magnetic Resonance Spectroscopy 21Leucovorin 21Irinotecan 21Oxaliplatin 19Biopsy 17Taxes 16pembrolizumab 15Cyclophosphamide 12Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8durvalumab 7Radiosurgery 7Nivolumab 7Carboplatin 7irinotecan sucrosofate 6dehydroftorafur 6Pemetrexed 6olaparib 5Radiotherapy 5Ipilimumab 5Erlotinib Hydrochloride 5Blood Specimen Collection 5trastuzumab deruxtecan 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × BAY 1895344 × 90 days × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡